Care organization and quality of life for people with chronic myeloid leukemia in the Lombardy hematology network

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls adults with CML who are followed at participating hematology outpatient clinics within the 21 REL centers in Lombardy to compare quality of life across different care models. Participants complete standardized patient-reported outcome tools (EORTC QLQ-C30 and CML24) and provide opinions about aspects of the quality of care they receive. Data on the organizational characteristics of each hematology center will be linked to patient-reported outcomes to explore associations. The study is led by the University of Milano-Bicocca with clinical activity based at Fondazione IRCCS San Gerardo dei Tintori in Monza.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects aged 18 years or older.
* Subjects diagnosed with Chronic Myeloid Leukemia.
* Subjects diagnosed with CML under care at the hematology outpatient clinics of the 21 REL centers.
* Subjects followed at the reference hematology center for a minimum of 6 months.
* Freely given informed consent obtained before the start of the study.

Exclusion Criteria:

* Subjects who have not given consent to participate in the study.
* Subjects who do not meet the inclusion criteria.

Where it's running

• Fondazione IRCCS San Gerardo dei Tintori
  Monza, Mb, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asciminib for chronic phase CML with T315I mutation

  This study tests asciminib 200 mg twice daily in adults with chronic phase CML and a T315I mutation after stem cell transplant to see if it helps control leukemia.

  Recruiting at 5 sites Phase 2 University of Jena · Aachen and 9 other locations · NCT07789574

• Early Tacrolimus Taper After Allogeneic Transplant

  This study tests whether stopping tacrolimus early after an allogeneic stem cell transplant is safe and feasible for people with AML, MDS, MF, CML, CMML, or GVHD risk after transplant.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07302776

• Using asciminib to treat chronic myeloid leukemia patients with a specific mutation

  This study is testing if a new drug called asciminib can help people with chronic myeloid leukemia who have a specific mutation and haven't had success with other treatments.

  Recruiting at 6 sites Phase 2 Novartis · Bordeaux and 5 other locations · NCT06514534

• Real-life data collection for patients with Chronic Myeloid Leukemia

  This study is collecting information from people with Chronic Myeloid Leukemia to see how different treatments work and how they affect patients over time.

  Recruiting at 14 sites University Hospital, Clermont-Ferrand · Annecy and 13 other locations · NCT05963061

• Second STOP After Pioglitazone Priming in CML Patients

  This phase 2 study tests whether adding pioglitazone to a TKI can help CML patients who lost major molecular response after stopping a TKI to regain disease control.

  Recruiting at 3 sites Phase 2 Versailles Hospital · Le Chesnay and 5 other locations · NCT02889003

• Combination treatment for BCR-ABL positive B-cell leukemia and chronic myeloid leukemia

  This study is testing a new combination treatment for people with BCR-ABL positive B-cell leukemia or chronic myeloid leukemia to see if it helps them feel better and works well with existing medications.

  Recruiting at 4 sites Phase 1 Dana-Farber Cancer Institute · Chicago, Illinois and 3 other locations · NCT03595917

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.